Dr Karishma Sethi-Arora(@gastrokari1986) 's Twitter Profile Photo

It was a pleasure to speak at Celltrion’s ‘IBD Masterclass’ 📚

With keynotes from Prof Limdi and Dr Phil Smith and a wonderful multi-disciplinary attendance, it really was a great evening.

Thank you @Celltrionhc . 💉💊🏥

It was a pleasure to speak at Celltrion’s ‘IBD Masterclass’ 📚

With keynotes from Prof Limdi and Dr Phil Smith and a wonderful multi-disciplinary attendance, it really was a great evening. 

Thank you @Celltrionhc . 💉💊🏥

#IBD #UC #Crohnsdisease #CCUK #gastroenterologist
account_circle
Martina Cooney(@Martina13670575) 's Twitter Profile Photo

Attending BSR British Society for Rheumatology in Manchester. Inspiring talks. By nurses, for nurses, amongst other amazing content. With thanks to @Celltrionhc.

Attending @RheumatologyUK British Society for Rheumatology in Manchester. Inspiring talks. By nurses, for nurses, amongst other amazing content. With thanks to @Celltrionhc.
account_circle
salim benkhalifa(@SBenkhalifa82) 's Twitter Profile Photo

It was a great honor to participate for the first time to AOCC 2023 in Busan (South Korea), great congress with great lectures and scientific updates. Thanks a lot to my @Celltrionhc and 셀트리온제약 colleagues for the kind invitation.

It was a great honor to participate for the first time to @aocc2023 in Busan (South Korea), great congress with great lectures and scientific updates. Thanks a lot to my @Celltrionhc and @CelltrionPh colleagues for the kind invitation.
account_circle
Spherix Rheumatology(@SpherixRheum) 's Twitter Profile Photo

@Celltrionhc announced the U.S. FDA has given its approval for Yuflyma (adalimumab-aaty), a biosimilar of Humira (adalimumab), in a high-concentration (100mg/mL) & citrate-free formulation and will be available in July 2023.

Read more: hubs.la/Q01RdG7f0

@Celltrionhc announced the U.S. FDA has given its approval for Yuflyma (adalimumab-aaty), a biosimilar of Humira (adalimumab), in a high-concentration (100mg/mL) & citrate-free formulation and will be available in July 2023. 

Read more: hubs.la/Q01RdG7f0
account_circle
Spherix Dermatology(@SpherixDerm) 's Twitter Profile Photo

@Celltrionhc announced the U.S. FDA has given its approval for Yuflyma (adalimumab-aaty), a biosimilar of Humira (adalimumab), in a high-concentration (100mg/mL) & citrate-free formulation and will be available in July 2023.

Read more: hubs.la/Q01RdDGV0

@Celltrionhc announced the U.S. FDA has given its approval for Yuflyma (adalimumab-aaty), a biosimilar of Humira (adalimumab), in a high-concentration (100mg/mL) & citrate-free formulation and will be available in July 2023. 

Read more: hubs.la/Q01RdDGV0
account_circle
Kymos(@KymosGroup) 's Twitter Profile Photo

▶ Our CEO, Joan Puig de Dou, and our Corporate Director for Business Development, Cosme Aragonés, have visited the headquarters of our partner @Celltrionhc.

Thank you for the warm welcome and your trust in Kymos throughout all this time.

▶ Our CEO, Joan Puig de Dou, and our Corporate Director for Business Development, Cosme Aragonés, have visited the headquarters of our partner @Celltrionhc.
 
Thank you for the warm welcome and your trust in Kymos throughout all this time.
account_circle
Celltrion(@Celltrioninc) 's Twitter Profile Photo

We have come close to the end of 2023, marking another year of . 2023 was full of milestones that will guide us next year.
Here are some of this year's highlights we wanted to share with you.
Thank you all for joining us on our journey.😊💝

account_circle
Celltrion(@Celltrioninc) 's Twitter Profile Photo

Greetings and Happy Holidays from all of us at !
As the Spirit of the Season fills the air, our colleagues around the world would like to extend our warmest holiday greetings and express our heartfelt gratitude for being with us.
!✨🎁

account_circle
medtoday Germany(@medtodaygermany) 's Twitter Profile Photo

Heute stellen wir Ihnen die persönlichen Highlight-Studien unserer Experten Prof. Sebastian Zeissig und Prof. Carsten Schmidt vor. 👉t1p.de/GASTROtoday_UE…
@Celltrionhc

account_circle
medtoday Germany(@medtodaygermany) 's Twitter Profile Photo

Prof. Dr. med. Carsten Schmidt präsentiert die wichtigsten Studien der zum Thema “Colitis ulcerosa”. Freuen Sie sich unter anderem auf die Ergebnisse der ARTEMIS-UC-Studie. Jetzt anschauen unter 👉t1p.de/gud1m @Celltrionhc

account_circle
Kymos(@KymosGroup) 's Twitter Profile Photo

▶ Our QP, Jon Azáceta Elzaurdi, has been auditing our client @Celltrionhc facilities in Korea.

We sincerely appreciate the warm welcome and the trust you have placed in Kymos throughout this time.

It is a true pleasure collaborating with Celltrion team!

▶ Our QP, Jon Azáceta Elzaurdi, has been auditing our client @Celltrionhc facilities in Korea.

We sincerely appreciate the warm welcome and the trust you have placed in Kymos throughout this time.

It is a true pleasure collaborating with Celltrion team!
account_circle
Celltrion(@Celltrioninc) 's Twitter Profile Photo

Colleagues from Celltrion USA visited HQ, sharing insights and forging stronger connections.
We will continue breaking through boundaries to improve the quality of lives of people in the US by providing high-quality medicines and making US healthcare more accessible.

Colleagues from Celltrion USA visited #Celltrion HQ, sharing insights and forging stronger connections.
We will continue breaking through boundaries to improve the quality of lives of people in the US by providing high-quality medicines and making US healthcare more accessible.
account_circle
NPQD Connolly Hospital Blanchardstown(@NPQD_CHB) 's Twitter Profile Photo

Faculty for Nursing Management in Chronic Disease meeting in CHB to share the career pathways open to nursing & management options for patients. Positive feedback from patients on impact of new treatment options @Celltrionhc

Faculty for Nursing Management in Chronic Disease meeting in CHB to share the career pathways open to nursing & management options for patients. Positive feedback from patients on impact of new treatment options #Biosimilars  #Rheumatology #IBD #Dermatology @Celltrionhc
account_circle
د. يوسف شمس الدين(@YAYshamsaldeen) 's Twitter Profile Photo

💉هيوميرا يحتوي على مادة
💉Adalimumab
يستخدم لعلاج الروماتيزم، كرونز، القولون التقرحي، الصدفية والتهاب العنبية👁

هيئة الغذاء والدواء U.S. FDA اعتمدت دواء مكافئ
💉Yuflymaيوفليما
يتميز
✅بتركيز عالي
✅خالي من السيترات (تحسس/ألم موضعي أقل)
@Celltrionhc
celltrionhealthcare.com/board/en_newsl…

💉هيوميرا يحتوي على مادة
💉Adalimumab
يستخدم لعلاج الروماتيزم، كرونز، القولون التقرحي، الصدفية والتهاب العنبية👁

هيئة الغذاء والدواء @US_FDA اعتمدت دواء مكافئ
💉Yuflymaيوفليما
يتميز
✅بتركيز عالي
✅خالي من السيترات (تحسس/ألم موضعي أقل)
@Celltrionhc
celltrionhealthcare.com/board/en_newsl…
account_circle
Dr Yoon-Kyo An(@DrYoonAn) 's Twitter Profile Photo

It was an absolute delight to attend two remarkable meetings in Jeju island in Korea. Fruitful discussions at the ASUC in Asia-Pacific symposium on collaborative research with Australia New Zealand IBD Consortium (ANZIBDC) and . Sharing important clinical trials and RWE data at @Celltrionhc Remsima symposium.

It was an absolute delight to attend two remarkable meetings in Jeju island in Korea. Fruitful discussions at the ASUC in Asia-Pacific symposium on collaborative research with @ANZIBDC and #AOCC. Sharing important clinical trials and RWE data at @Celltrionhc Remsima symposium.
account_circle